Muscle tenderness, unexplained weakness, or loss of appetite are early signs of myeloma and can be observed by both patients and caregivers. They are important not only because they alert both the patients and the caregivers to the presence of myeloma but because they allow clinicians to confirm the diagnosis early. The pain caused by myeloma and
Multiple myeloma is a chronic blood disease in which bone marrow-derived plasma cells are made abnormally. As a result, blood clots may form in the bloodstream and block arteries or veins. These clots can cause painful or fatal ischemic events.\n\nThe purpose of this article is to describe the types of cancer and to provide a brief review of the risk factors associated with cancer.
An estimated 1 in 25,000 US adults are diagnosed with multiple myeloma a year. The disease most commonly affects whites and men aged 70 or older. Multiple myeloma is strongly linked with multiple myeloma mortality.
Although multiple myeloma is a rare bone disease, multiple myeloma may be the most common bone disorder with a high likelihood of the disease occurring in the elderly populations. It was found the risk of multiple myeloma would be 3- to 4-times if the patient was diagnosed with an autoimmunity, especially if the autoimmunity was caused by the use of bisphosphonate medications.
The use of a standardized induction regimen followed by BCT is associated with substantial improvements in both event-free and overall survival in newly diagnosed patients with MM, similar to that seen with high-risk standard-risk patients.
Although no drugs are known to be curative for multiple myeloma, many therapies have been found to improve both survival and quality of life for those who survive this disease. Targeted therapies include immunotherapy or immunomodulatory agents, which target the immune system; and immunosuppressive agents, which impair the immune system. New biologic drugs targeting specific proteins and receptors have also emerged; however, their role in treating multiple myeloma remains obscure. The prognosis of multiple myeloma is difficult to predict, largely due to the highly variable response to treatment. Despite our better understanding of the disease, many patients still respond poorly to treatment. New agents are likely to have profound impact on the course of this disease.
The survival rate for patients with multiple myeloma depends on the type of treatment they receive and how long they have a stable treatment plan. If people keep on receiving treatment, the percentage of cancer death that is related to cancer slowly but persistently decreases. It is important to be aware that a diagnosis of multiple myeloma does not mean that a person is going to die. The survival rate varies among patient populations. Therefore, it is hard to give an average survival rate. For example, people being treated more intensively are likely to live longer than persons from other groups. Another way patients, families of patients, and their physicians, need to keep aware is to make careful decisions on the type and number of treatments.
Patients with multiple myeloma should reduce their steroid medication and should not take it after a bout of fevers with a high cytokine peak (IL-6 or TNF-α).
Given the lack of clinical trials evaluating the long-term effects of corticosteroids, it is difficult to make conclusions about them. We argue that since they are an extremely commonly used drug with a relatively good side effect profile, further studies of this drug are still warranted.
Multiple myeloma does not spread very quickly. This is of concern because it is an incurable disease. There is no cure for multiple myeloma as we know it. There is still a long way to go to find an effective cure for the disease.
Findings from a recent study of this study show that the risk of death in patients with myeloma is higher than average. This data should be taken into account in discussions that occur when treatment protocols for this disorder are being developed.
The study results suggest that multiple myeloma runs in families. Findings from a recent study confirm the theoretical prediction that in a genetic study of multiple myeloma, one should expect to find a high concordance rate between families ascertained from an unrelated sample and a sample ascertained from a multiple myeloma-affected individual.